Eloxx Pharmaceuticals. has filed a patent for macrolide compounds that can be used to treat infectious diseases caused by Gram-negative bacteria. The compounds include 14-membered ketolides and 14-15-membered azaketolides, and may have a bicyclic structure. The patent also covers methods of preparing these compounds, allowing for easier access to previously challenging-to-make macrolides. GlobalData’s report on Eloxx Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Eloxx Pharmaceuticals, RNAi pest resistance was a key innovation area identified from patents. Eloxx Pharmaceuticals's grant share as of September 2023 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Macrolide compounds for treating infectious diseases
A recently filed patent (Publication Number: US20230242565A1) describes a series of compounds and their pharmaceutical compositions for the treatment of infectious diseases. The patent claims a compound of Formula (I), which can further be categorized into various sub-formulas such as (I-a), (I-b), (I-c), (I-d), (I-f-i), (I-f-ii), (I-h-i), (I-h-ii), (I-j-i), (I-j-ii), (I-k), and (I-l). These compounds can also be in the form of pharmaceutically acceptable salts. The patent also claims compounds of Formula (II) and its sub-formulas (II-a) and (II-b), as well as compounds of Formula (III) and its sub-formulas (III-a) to (III-j). Additionally, the patent claims compounds of Formula (IV) and its sub-formulas (IV-a) to (IV-k).
The patent further describes pharmaceutical compositions comprising these compounds and their pharmaceutically acceptable salts, along with suitable excipients. It also includes a kit for treating infectious diseases, which contains the compound or composition and instructions for administration. The patent claims a method of treating infectious diseases by administering an effective amount of the compound or composition to a subject in need. The infectious diseases can be bacterial or parasitic infections, including those caused by Gram-positive or Gram-negative bacteria such as Staphylococcus, Acinetobacter, Klebsiella, Escherichia, or Pseudomonas.
The patent also discloses methods of preparing the claimed compounds, involving various synthetic steps such as protecting, alkylating, reducing, deprotecting, oxidizing, and cyclizing reactions. The methods utilize starting materials of specific formulas, and the resulting compounds can be further modified or deprotected to obtain the desired compounds of Formulas (I-a), (II-a), (III-a), and (IV-a). The patent provides specific examples and conditions for these synthetic methods.
Overall, this patent presents a series of compounds and their pharmaceutical compositions for the treatment of infectious diseases, particularly bacterial infections. The patent also discloses methods of preparing these compounds, providing potential options for the development of new therapeutic agents.
To know more about GlobalData’s detailed insights on Eloxx Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
